Want to see IMVT full AI Analyst Report?
Immunovant (IMVT) Ratios
Immunovant Ratios
IMVT's free cash flow for Q1 2027 was $-124.41M. For the 2027 fiscal year, IMVT's free cash flow was increased by $0.00 and operating cash flow was $-124.41M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 |
| Quick Ratio | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 |
| Cash Ratio | 8.64 | 10.38 | 13.07 | 8.70 | 11.09 |
| Solvency Ratio | -4.81 | -6.01 | -5.29 | -4.86 | -3.42 |
| Operating Cash Flow Ratio | -3.90 | -5.47 | -4.41 | -4.35 | -2.38 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -1552.37 | 0.00 | 0.00 |
| Net Current Asset Value | $ 843.84M | $ 698.89M | $ 616.82M | $ 360.99M | $ 467.19M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.12 | 1.10 | 1.08 | 1.12 | 1.10 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -1960.47 | -16.67 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -16.69 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.11 | 0.02 |
| Net Debt to EBITDA | 1.79 | 1.73 | 2.35 | 1.80 | 3.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.04% | 100.22% | 100.22% | 100.00% | 99.95% |
| EBT Per EBIT | 94.84% | 94.25% | 95.77% | 101.28% | 100.50% |
| Return on Assets (ROA) | -52.80% | -53.31% | -38.90% | -51.98% | -30.40% |
| Return on Equity (ROE) | -59.30% | -58.50% | -41.98% | -58.20% | -33.36% |
| Return on Capital Employed (ROCE) | -62.46% | -61.93% | -43.72% | -57.45% | -33.12% |
| Return on Invested Capital (ROIC) | -62.46% | -61.93% | -43.71% | -57.26% | -33.03% |
| Return on Tangible Assets | -52.80% | -53.31% | -38.90% | -51.98% | -30.40% |
| Earnings Yield | -11.16% | -15.98% | -5.94% | -11.05% | -25.93% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6729.74 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 6729.74 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.23 | -2.48 | -1.55 | -1.53 | -0.97 |
| Free Cash Flow Per Share | -2.23 | -2.48 | -1.55 | -1.53 | -0.97 |
| Dividend Paid and CapEx Coverage Ratio | -50913.75 | -495.22 | -595.08 | -955.29 | -417.76 |
| Capital Expenditure Coverage Ratio | -50913.75 | -495.22 | -595.08 | -955.29 | -417.76 |
| Operating Cash Flow Coverage Ratio | -5657.08 | -3835.45 | -1552.37 | -154.26 | -44.89 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -8.99% | -14.54% | -4.92% | -9.87% | -17.60% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.97 | -6.26 | -16.83 | -9.05 | -3.86 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 5.31 | 3.66 | 7.07 | 5.27 | 1.29 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.12 | -6.88 | -20.34 | -10.13 | -5.68 |
| Price-to-Operating Cash Flow Ratio | -11.13 | -6.89 | -20.38 | -10.14 | -5.70 |
| Price-to-Earnings Growth (PEG) Ratio | -6.12 | -0.14 | -1.69 | -0.46 | -0.22 |
| Enterprise Value Multiple | -7.19 | -4.55 | -13.82 | -7.37 | -0.72 |
| Enterprise Value | 3.63B | 1.88B | 3.73B | 1.53B | 112.88M |
| EV to EBITDA | -7.19 | -4.55 | -13.82 | -7.37 | -0.72 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -8.91 | -4.98 | -17.38 | -8.14 | -1.06 |
| EV to Operating Cash Flow | -8.91 | -4.99 | -17.41 | -8.15 | -1.06 |
| Tangible Book Value Per Share | 4.67 | 4.67 | 4.47 | 2.95 | 4.28 |
| Shareholders’ Equity Per Share | 4.67 | 4.67 | 4.47 | 2.95 | 4.28 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.96 | 1.01 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.81 | 0.91 | 0.83 | 0.89 | 0.68 |
Currency in USD